Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
-
Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older
Blujepa is the first in a new class of oral antibiotics for uUTIs in nearly 30 years.
Download (PDF, 140.8KB) -
GSK, UK Dementia Research Institute (UK DRI) and Health Data Research UK (HDR UK) to collaborate on first-of-its-kind dementia research initiative
New collaboration aims to deepen understanding of neurodegeneration using the UK’s unique health data ecosystem.
Download (PDF, 150.0KB) -
GSK’s application to expand use of Nucala (mepolizumab) for the treatment of COPD accepted for review by the European Medicines Agency
Nucala (mepolizumab) could be the first biologic with monthly dosing for patients with COPD, if approved
Download (PDF, 146.5KB) -
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Results from the study demonstrate that N6LS effectively maintained undetectable viral load when combined with long-acting cabotegravir.
Download (PDF, 230.3KB) -
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
New data at CROI 2025 show zero cases of HIV acquisition reported with Apretude in varied clinical settings and populations.
Download (PDF, 227.8KB) -
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
Results illustrate ViiV Healthcare’s pipeline is generating multiple options for the development of new ultra long-acting HIV regimens.
Download (PDF, 174.9KB) -
ViiV Healthcare continues to deliver long-acting injectable HIV innovation with late-breaking data and real-world insights across pipeline and portfolio at CROI 2025
Real-world and implementation data highlight effectiveness of Cabenuva and Apretude.
Download (PDF, 205.6KB) -
GSK to showcase latest research at the International RSV Symposium to advance RSV prevention in adults
17 abstracts to evaluate unmet medical need and approaches to RSV prevention in adults.
Download (PDF, 131.7KB) -
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
Download (PDF, 164.3KB) -
Depemokimab delivers clinically meaningful and statistically significant improvements for patients with chronic rhinosinusitis with nasal polyps (CRSwNP)
ANCHOR-1 and ANCHOR-2 phase III trials show improvements in nasal polyp size and obstruction for depemokimab with twice-yearly dosing.
Download (PDF, 181.4KB) -
GSK plc commences share buyback programme
GSK plc announces the commencement of its share buyback programme, as announced in its 2024 full year results announcement.
Download (PDF, 114.3KB) -
GSK completes acquisition of IDRx, Inc.
GSK plc has completed the acquisition of IDRx, Inc. (IDRx), a Boston-based, clinical-stage biopharmaceutical company.
Download (PDF, 143.1KB) -
GSK announces Dr Gavin Screaton to join the Board as Non-Executive Director
GSK plc has today announced that Dr Gavin Screaton has been appointed to the Board of the Company as a Non-Executive Director.
Download (PDF, 129.2KB) -
Nucala (mepolizumab) application for COPD accepted for review in China
Around 100 million people live with COPD in China, accounting for almost 25% of all COPD cases globally
Download (PDF, 179.3KB) -
Penmenvy, GSK’s 5-in-1 meningococcal vaccine, approved by US FDA to help protect against MenABCWY
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y).
Download (PDF, 187.8KB) -
GSK delivers strong 2024 performance with further improvement to long-term growth outlook
Q4 and full year 2024 performance highlights
Download (PDF, 853.9KB) -
European Commission authorises ViiV Healthcare’s long-acting injectable Vocabria + Rekambys for HIV treatment in adolescents
Vocabria + Rekambys (cabotegravir + rilpivirine) is the first and only complete long-acting injectable for the treatment of HIV.
Download (PDF, 146.2KB) -
Depemokimab accepted for review by the European Medicines Agency for use in asthma with type 2 inflammation and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing.
Download (PDF, 155.4KB) -
Depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP
If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing
Download (PDF, 194.1KB) -
GSK and Oxford establish the GSK-Oxford Cancer Immuno-Prevention Programme to advance novel cancer research
Collaboration unites GSK and Oxford’s complementary expertise in the science of the immune system, vaccines and cancer biology.
Download (PDF, 173.0KB)
